Dasatinib‐induced hypoglycemia in a patient with acute lymphoblastic leukemia

Tyrosine kinase inhibitors can cause significant hypoglycemia in patients with diabetes on other antihyperglycemic medications. These patients should be monitored, and their medications adjusted accordingly. Tyrosine kinase inhibitors can cause significant hypoglycemia in patients with diabetes on o...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 8; no. 7; pp. 1238 - 1240
Main Authors Lundholm, Michelle D., Charnogursky, Gerald A.
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.07.2020
John Wiley and Sons Inc
Wiley
Subjects
acute lymphoblastic leukemia
adverse effect
Cardiovascular disease
Case Report
Case Reports
Diabetes
Glucose
Hypoglycemia
Insulin
Kinases
Leukemia
Metabolism
Mutation
Patients
tyrosine kinase inhibitor
tyrosine kinase inhibitor
adverse effect
acute lymphoblastic leukemia
diabetes
hypoglycemia
Online AccessGet full text

Cover

More Information
Summary:Tyrosine kinase inhibitors can cause significant hypoglycemia in patients with diabetes on other antihyperglycemic medications. These patients should be monitored, and their medications adjusted accordingly. Tyrosine kinase inhibitors can cause significant hypoglycemia in patients with diabetes on other antihyperglycemic medications. These patients should be monitored, and their medications adjusted accordingly.
Bibliography:An abstract based on this article was presented at The American Association of Clinical Endocrinologists national conference in April, 2019.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.2901